The lawsuit, Holtzman v. Beta Bionics, Inc., contends that the medical device manufacturer suppressed reports of over 18,000 user complaints. These reports, documented in a June 2025 FDA Form 483, highlighted instances of life-threatening hypoglycemia linked to the device’s automated insulin dosing algorithm. Plaintiffs argue the company failed to investigate these malfunctions or implement necessary corrective measures.

Financial fallout from these disclosures was significant. Shares of BBNX plummeted 37% on January 9, 2026, after the company revealed that new patient adoption rates had fallen short of analyst projections by nearly 10%. A subsequent 4.9% decline followed in late February 2026, when the FDA publicly released a warning letter detailing the company's failure to report device-related adverse events. Represented by Bleichmar Fonti & Auld LLP, the class action seeks damages under the Securities Exchange Act of 1934 for investors who purchased stock during the period the company allegedly touted superior clinical outcomes while ignoring internal safety red flags.